NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis $5.28 +0.16 (+3.13%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Codexis Stock (NASDAQ:CDXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Codexis alerts:Sign Up Key Stats Today's Range$5.07▼$5.4850-Day Range$2.91▼$5.8152-Week Range$2.53▼$6.08Volume3.25 million shsAverage Volume569,688 shsMarket Capitalization$429.68 millionP/E RatioN/ADividend YieldN/APrice Target$8.33Consensus RatingModerate Buy Company OverviewCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More… Codexis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks83rd Percentile Overall ScoreCDXS MarketRank™: Codexis scored higher than 83% of companies evaluated by MarketBeat, and ranked 177th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCodexis has only been the subject of 2 research reports in the past 90 days.Read more about Codexis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.11% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Codexis has recently increased by 2.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Sustainability and ESG2.5 / 5Environmental Score-3.67 Percentage of Shares Shorted2.11% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Codexis has recently increased by 2.38%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News SentimentN/A News SentimentCodexis has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Codexis this week, compared to 2 articles on an average week.Search Interest5 people have searched for CDXS on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $146,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Codexis' insider trading history. Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Stock News HeadlinesCodexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last weekDecember 14, 2024 | finance.yahoo.comCodexis Announces New Employment Inducement GrantsDecember 6, 2024 | globenewswire.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 22, 2024 | Behind the Markets (Ad)Cantor Fitzgerald Keeps Their Buy Rating on Codexis (CDXS)November 23, 2024 | markets.businessinsider.comCodexis to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 19, 2024 | globenewswire.comStifel Nicolaus Remains a Buy on Codexis (CDXS)November 15, 2024 | markets.businessinsider.comCodexis (CDXS) Receives a Hold from TD CowenNovember 15, 2024 | markets.businessinsider.comCodexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi TherapeuticsNovember 14, 2024 | globenewswire.comSee More Headlines CDXS Stock Analysis - Frequently Asked Questions How have CDXS shares performed this year? Codexis' stock was trading at $3.05 at the beginning of the year. Since then, CDXS stock has increased by 73.1% and is now trading at $5.28. View the best growth stocks for 2024 here. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) issued its earnings results on Thursday, October, 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.04. The biotechnology company earned $12.83 million during the quarter, compared to the consensus estimate of $11.64 million. Codexis had a negative net margin of 96.35% and a negative trailing twelve-month return on equity of 71.56%. Who are Codexis' major shareholders? Top institutional shareholders of Codexis include FMR LLC (5.53%), Baillie Gifford & Co. (2.23%), Geode Capital Management LLC (2.02%) and State Street Corp (1.91%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett, Margaret Nell Fitzgerald and Dennis P Wolf. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings10/31/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Industrial organic chemicals Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees250Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$11.00 Low Stock Price Target$5.00 Potential Upside/Downside+57.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,240,000.00 Net Margins-96.35% Pretax Margin-96.25% Return on Equity-71.56% Return on Assets-38.00% Debt Debt-to-Equity Ratio0.39 Current Ratio3.21 Quick Ratio3.15 Sales & Book Value Annual Sales$64.45 million Price / Sales6.67 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book4.26Miscellaneous Outstanding Shares81,378,000Free Float79,669,000Market Cap$429.68 million OptionableOptionable Beta2.15 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:CDXS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.